Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptomic analyses of SLC5A8-deficient and wild-type mouse brains.

ABSTRACT: We used transcriptomic analyses of whole brain homogenates from SLC5A8-deficient and wild-type mice at ages of 4 and 18 months to study the expression of genes encoding proteins that are involved in ketogenic amino acid and lipid catabolism.

ORGANISM(S): Mus musculus

PROVIDER: GSE117705 | GEO | 2018/07/27

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Transcriptome response of mouse mammary gland from age 12 to 30 months of age in Esr1 and CYP19A1 genetically engineered mouse models of breast cancer risk in the presence and absence of transgene induction

Project description:Breast cancer is an age-related cancer in women with two peaks, one at 50 and one at 70 years of age. Here we used two conditional genetically engineered mouse models of breast cancer risk to study mammary gland transcriptional changes that occur as female mice age from 12 to 30 months of age, paralleling aging from 58 to 85 years of age in women. The two models express either mammary epithelial cell-targeted Estrogen Receptor (ER) alpha (Esr1) or Aromatase (CYP19A1A) over-expression beginning at age 12 or 18 months of age. Both of these risk factors increase estrogen pathway signaling, either directly though the receptor or by increasing local estrogen production. The goals of the study are to determine how quickly significant transcriptional changes occur in the mammary gland following transgene induction, to determine how the transcriptome becomes modified as the mice age past reproductive senescence through old and very old life stages, and to identify similarities and differences in the transcriptomes between the two risk conditions at different ages and conditions. The first specific objective of this transcriptome-based study is to identify significantly differentially expressed genes within each model between different ages and times of transgene induction. This includes transcriptional changes induced by 1 week, 6, 12 and 18 months of transgene expression with transgene expression initiated at age 12 months as well as transcriptional changes induced by 1 week and 6 months of transgene expression initiated at age 18 months. The second specific objective is to compare the two models at different ages (12, 18, 24 and 30 months of age) and different transgene induction times (6, 12 and 18 months) to identify differentially expressed genes between the models. Comparative control mice from each model include age 18- and 24-month-old mice without transgene induction.

2022-08-22 | GSE201767 | GEO

Age-associated changes in murine endothelial gene expression correlate with impaired blood-brain barrier integrity and elevated risk of intracerebral hemorrhage.

Project description:We studied changes in gene expression in Endothelial Cells isolated from murine brains of increasing ages of 2, 6, 12, 18, and 24 months. We then performed linear regression analysis to compare the changes in gene expression in the endothelial cells with age.

2023-09-20 | GSE216004 | GEO

Dunaliella tertiolecta UTEX 'LB 999'

Project description:Amino acid catabolism fuels microalgal lipogenesis

| PRJNA324164 | ENA

RNA-seq of C.elegans and M.musculus in the presence and absence of D-Glucosamine (GlcN)

Project description:D-Glucosamine (2-amino-2-deoxy-D-glucose, C.A.S.# 3416-24-8) (GlcN) is a freely available and commonly used dietary supplement possibly promoting cartilage health in humans which also acts as an inhibitor of glycolysis. We here find that GlcN extends C. elegans lifespan by impairing glucose metabolism to activate AMP-activated protein kinase (AMPK/AAK2) leading to increased mitochondrial biogenesis. Consistent with the concept of mitohormesis, this promotes increased formation of mitochondrial reactive oxygen species (ROS) and p38/PMK-1-mediated stress signaling culminating in increased expression of the nematodal amino acid-transporter 1 (aat-1) gene. Ameliorating mitochondrial ROS formation as well as impairment of aat-1-expression abolishes GlcN-mediated lifespan extension in a NRF2/SKN-1-dependent fashion. Notably and unlike other calorie restriction mimetics (CRM) like 2-deoxy-D-glucose (2DG, DOG), GlcN extends lifespan of aging C57BL/6 mice (log-rank: p=0.002; cox regression: p=0.01) similarly paralleled by an induction of mitochondrial biogenesis, increased expression of several murine amino acid transporters, as well as increased amino-acid catabolism. Taken together, GlcN mimics a ketogenic diet to extend healthspan in evolutionary distinct species. 24 samples: 12 mRNA profiles of C.elegans: 6 without GlcN and 6 with GlcN supplementaion; 12 mRNA profiles of M.musculus: 6 without GlcN and 6 with GlcN supplementaion

2014-03-07 | E-GEOD-54853 | biostudies-arrayexpress

Liver Transcriptomics from Male and Female HET3 Mice on Control, Low Amino Acid and Low Isoleucine Diets when started in Young and Middle Aged Mice

Project description:Mice were put on either a control, low amino acid or low isoleucine diet at 9 weeks of age or 6 months of age and their liver transcriptomic expression was measured after 14 weeks and 18 months respectively on diet after an overnight fast. This was to discover the impact of sex, protein and isoleucine level on the metabolism of the liver.

2023-11-07 | GSE241904 | GEO

RNA-seq of C.elegans and M.musculus in the presence and absence of D-Glucosamine (GlcN)

2014-03-07 | GSE54853 | GEO

Taurine transporter (SLC6A6)-deficient skeletal muscle

Project description:Analysis of skeletal muscle from taurine transporter (TauT) knockout mice at 3 or 18 months of age. Knocking out TauT result in a decrease in muscle cell size, impaired exercise capacity and accelerated muscle aging. Results provide molecular insights into physiological role of taurine.

2014-05-08 | GSE57373 | GEO

Staging Alzheimer’s disease in brains and retinas of APP/PSEN1 mice by transcriptional profiling

Project description:Alzheimer’s disease (AD) is a common form of dementia characterized by amyloid plaque deposition, TAU pathology, neuroinflammation and neurodegeneration. Mouse models recapitulate some key features of AD. For instance, the B6.APP/PS1 model (carrying human transgenes for mutant forms of APP and PSEN1) shows plaque deposition and associated neuroinflammatory responses involving both astrocytes and microglia beginning around 6 months of age. However, in our colony, TAU pathology, significant neurodegeneration and cognitive decline are not apparent in this model even at older ages. Therefore, this model is ideal for studying neuroinflammatory responses to amyloid deposition. Here, RNA sequencing of brain and retinal tissue, generalized linear modeling (GLM), functional annotation followed by validation by immunofluorescence (IF) was performed in B6.APP/PS1 mice to determine the earliest molecular changes prior to and around the onset of plaque deposition (2-6 months of age).

2019-11-25 | GSE136861 | GEO

RNA-seq of livers from glucagon receptor knock-out (GcgrKO) mice compared to wildtype littermates

Project description:Glucagon is a key regulator of glucose homeostasis, amino acid catabolism, and lipid metabolism. Glucagon receptor knock-out (GcgrKO) mice have slightly reduced blood glucose levels whereas plasma levels of amino acids are vastly increased reflecting disruption of hepatic amino acid catabolism. To dissect the molecular mechanisms underlying this effect, RNA sequencing of livers from male GcgrKO mice and wild-type littermates were performed. The mice were 10 weeks of age and were subjected to a short-term fast of 4 h before anesthesia with 2.5% isoflurane.

2022-10-11 | E-MTAB-12060 | biostudies-arrayexpress

Analysis of human tau and age dependent changes in the synaptic and non-synaptic mitochondrial proteomes of the htau model of tauopathy

Project description:We investigated the effects of human tau on subcellular populations of the brain mitochondrial proteome in vivo using transgenic htau mice at ages preceding (5 months) and coinciding with (8 months) onset of tauopathy.

2022-02-28 | PXD030950 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data